Many transporters of gram-negative bacteria involved in the extracellular secretion of proteins and the efflux of toxic molecules operate by forming intermembrane complexes. These complexes are proposed to span both, inner and outer membranes and create a bridge across the periplasm. In this study, we analyzed interactions between the inner and outer membrane components of the tri-partite multidrug efflux pump AcrAB-TolC from Escherichia coli. We found that once assembled, the intermembrane AcrAB-TolC complex is stable during the separation of the inner and outer membranes, and subsequent purification. All three components of the complex co-purify when the affinity tag is attached to either of the proteins suggesting bi-partite interactions between AcrA, AcrB, and TolC. We show that antibiotics, the substrates of AcrAB-TolC stabilize interactions within the complex. However, the formation of the AcrAB-TolC complex does not require an input of energy.
INTRODUCTION
A distinctive feature of Gram-negative bacteria is the presence of the inner (IM) 1 and outer (OM) membranes. The two membranes are separated by an aqueous compartment called the periplasm, which provides a microenvironment of small molecules that buffer the cell from changes in its local surrounding. In fulfilling this essential role, the periplasm is not static but a dynamic cell compartment, which changes in response to external and internal stimuli (1).
The dynamic structure of a periplasm creates a special problem for the transport of diverse molecules into and out of a bacterial cell. To avoid the diluting effect of the periplasm, all molecules destined into an external medium or into a cytoplasm must pass the two membranes in a coordinated
manner. Yet the dynamic structure of the periplasm should not be compromised. An ultimate solution to the coordination of processes spatially separated into two different membranes is the existence of intermembrane multiprotein complexes that span both membranes and create a bridge across the periplasm. In this case, the transport is achieved without a periplasmic intermediate. Numerous
transporters of gram-negative bacteria involved in the extracellular secretion of protein and the efflux of toxic molecules were shown to operate by forming intermembrane complexes (reviewed in (2, 3) ). In the latter case this feature is particularly important since accumulation of periplasmic intermediates could lead to cell death. Although highly efficient in transport, the intermembrane complexes create tight links between the inner and outer membranes and thus, could impede the plasticity of the periplasm. How such complexes operate without compromising the dynamic nature of the periplasm remains unclear.
One possibility is that the intermembrane complexes are also dynamic structures and assemble only in the presence of specific substrates. Such a mechanism was proposed for the export of α-hemolysin by HlyBD-TolC complex from Escherichia coli. Here, the inner membrane complex HlyBD was shown proton-motive force. Three charged amino acid residues D407, D408 and K940 located in the transmembrane segment 4 and 10 were proposed to form a proton translocating pathway in AcrB and its close homologs (13, 14) . Mutations in these amino acid residues result in a complete inactivation of the transporter. In crystals, AcrB is a trimer (14, 15) in concert with the trimeric arrangements of AcrA (12) and the OM component of this complex TolC (16) . The structural signature of AcrB is a large periplasmic domain, which was shown to play a central role in drug recognition and transport (17, 18) . The top of this trimeric periplasmic domain forms a funnel, and the edge of the funnel has the dimensions that would fit with the tip of the periplasmic helical barrel of TolC (16) . This periplasmic barrel of TolC is about 70 Å long and could reach halfway across the periplasm. This observation prompted a model that AcrB could reach across the periplasm to bind to TolC (14) .
EXPERIMENTAL PROCEDURES

Bacterial strains and plasmids
E. coli strains and plasmids used in this study are listed in Table 1 . The affinity (6His)-tag was introduced by the PCR. All primer sequences are available upon request. The pUC151A plasmid was used as a template to construct pA His B and pAB His , and the pTrc99A-TolC plasmid was used as a template for construction of pTolC His . Native AcrB contains two C-terminal histidine residues. To construct the pAcrAB His plasmid, 1331 bp PCR fragment of the acrB gene with four additional histidine residues was digested with Hpa I and Nsi I restriction enzymes and inserted into the pUC151A plasmid, treated with the same enzymes. The pAcrA His B plasmid was constructed by the replacement of a Msc I-Xba I fragment of pUC151A with a PCR-amplified acrA containing (6His)-tag. The resultant plasmid was then treated with Xba I and Sph I restriction enzymes and ligated with the PCR-amplified acrB gene to produce pAcrA His 
Media, bacterial growth and MIC determinations
All bacterial cultures were grown at 37°C in Luria-Bertani (LB) broth or agar (10 g of Bactotryptone, 5 g of Yeast extract, and 5 g of NaCl per liter). Antibiotics ampicillin (100 µg/ml), kanamycin (35 µg/ml), spectinomycin (50 µg/ml), tetracycline (25 µg/ml) and chloramphenicol (25 µg/ml) were used for the selection where indicated. Minimal inhibitory concentrations (MICs) of various antimicrobial agents were determined as described (17) .
Protein purification
Native AcrB was purified from E. coli ECM2112 containing pUC151A plasmid as described previously (7) . Unlipidated AcrA His was purified from E. coli strain AG100AX containing pUZ10 plasmid as described (10) .
For purification of native TolC without (6His)-tag, the E. coli strain AG100AX containing pTrc99A-TolC plasmid was grown in 1 l of LB medium with ampicillin (100 µg/ml) to OD 600 ~ 0.6, then the expression of TolC was induced by 0.1 mM isopropyl-1-thio-β-Dgalactopyranoside (IPTG) for 3 h. Preparation of membrane fractions and purification steps were done as described before (19) with minor modifications. Purified TolC was also used to raise polyclonal antibody in rabbits.
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Protein assays and analysis
Protein concentrations were determined using DC Protein Assay (BioRad) with BSA as a standard. SDS-PAGE and immunoblotting were performed by standard techniques. When indicated in Figures, the reducing agent DTT and heat denaturation step were omitted from the sample preparation procedure. In all other cases, DTT was added to protein samples as a part of the SDS-sample buffer just prior to the electrophoresis. Proteins were visualized with anti-AcrA,
anti-AcrB and anti-TolC rabbit polyclonal antibodies and the alkaline-phosphatase-conjugated anti-rabbit antibody (Sigma) (7).
To determine the intracellular concentrations of AcrA, AcrB and TolC and the amounts of co-purified proteins we used a quantitative immunoblotting approach. Whole cell lysates, membrane fractions or purified proteins were separated by the SDS-PAGE. AcrA, AcrB or TolC were detected using immunoblotting with corresponding polyclonal antibodies. For each experiment, the respective purified proteins in increasing concentrations were loaded onto the same gels to serve as standards for the calibration. The alkaline-phosphatase-conjugated secondary antibody and the chromogenic reaction with 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium substrates were used to visualize protein bands. Quantification of immunoblots was done on GS710 Calibrated Imaging Densitometer (BioRad).
Sucrose-density gradient fractionation
Cells were grown to OD 600 of 0.6-0.8 in 50 ml of LB medium with an appropriate antibiotic and collected by centrifugation. Disruption of cells by EDTA-lysozyme treatment was performed as described previously (20) . Spheroplasts were fragmented into membrane vesicles by sonication (Misonix Inc., XL 2020) for 45 sec on ice. Then, the membrane vesicles in 20% sucrose solution containing 5 mM EDTA (pH 8.0) were layered as 1.6 ml fractions on a two-step gradient consisting of 3.2 ml of 60% sucrose and 7.5 ml of 25% sucrose. All subsequent steps for membrane purification and floatation were performed as described by Ishidate et. al. (1986) .
Briefly, after centrifugation in a Beckman SW40 rotor at 40,000 rpm for 3.5 hrs two adjacent bands at 25%-60% sucrose interface were collected together by puncturing the side of the tube with a needle attached to a syringe. The resulting suspension (0.6-0.9 ml) was diluted with 5mM
EDTA and was then applied on the top of 11 ml 30-60% (w/w) sucrose gradient. Samples were centrifuged at 100,000g for 18 h and fractions (0.1-0.2 ml) were collected from the bottom of the centrifuge tube. Separated IM and OM samples were further subjected to a floatation gradient centrifugation at 100,000g for 20 h. After centrifugation all fractions were analyzed by the SDS-PAGE and visualized by the silver staining technique or Western blotting. The NADH-oxidase activity was measured as before (20) . Sucrose concentrations (%) were converted into density values (g/ml) using tabulated values for sucrose in water at 5°C (21) .
Co-purification experiments
For co-purification experiments, E. coli cells carrying the corresponding plasmids were grown in 0.5 L of LB medium with ampicillin (100 µg/ml) to OD ~ 0.8-1.0, collected by centrifugation and resuspended in 5 ml of buffer containing 10 mM Tris-HCl and 5 mM EDTA (pH 8.0). All centrifugation steps were carried out at +4°C. We found that the cell lysis by French Press led to the disruption of the AcrAB-TolC complexes. Therefore, in all co-purification experiments we used EDTA-lysozyme treatment followed by osmotic shock to convert cells into spheroplasts. OD 600 of 0.6-0.8 in 100 ml of LB medium with ampicillin (100 µg/ml). Cells were collected by centrifugation, washed in K-Na phosphate buffer (pH 7.4), resuspended in the same buffer and incubated with carbonyl cyanide m-chlorophenyl hydrazone (CCCP) in concentrations of 5, 20 or 100 µM, puromycin (PUR) (64 µg/ml), oleandomycin (OLE) (250 µg/ml) , proflavine (PRO) (12.5 µg/ml) and Phe-Arg β-naphtylamide (MC-207,110) (5 µg/ml) for 30 min at 37°C. After incubation cells were collected by centrifugation, resuspended in buffer (10 mM Tris-HCl (pH 8.0), 5 mM EDTA (pH 8.0)) and subjected to the osmotic EDTA-lysozyme lysis. The (6His)-tagged proteins were purified as described above.
Chemical cross-linking
Chemical in vivo cross-linking was carried out as described previously (12) . Dithiobissuccinimidylpropionate (DSP) in concentration of 400 µM was used as a cross-linking agent. Reaction mixtures were incubated at +37°C for 30 min. Cross-linking was terminated by adding Tris-HCl (pH 7.2) to the final concentration of 75 mM. For the analysis of the cross-linked complexes reducing agents were omitted from the sample buffer.
RESULTS
AcrA and AcrB co-migrate with both the inner and outer membranes in sucrose density gradient
To elucidate how the intermembrane AcrAB-TolC complex is assembled, we first determined the distribution of AcrA, AcrB and TolC proteins in membrane fractions after separation of the IM and OM by sucrose density equilibrium centrifugation ( Fig. 1 ). For this purpose, E. coli cells were converted into spheroplasts by EDTA-lysozyme treatment (20) . Crude membranes were first purified by sedimentation in a two-step sucrose gradient and then subjected to sedimentation through a 30%-60% sucrose gradient, (Fig. 1A ). Previous reports indicated that trimeric, fully assembled TolC is located exclusively in the OM (19) . Similarly, using immunoblotting with anti-TolC antibody we found trimeric TolC only in the OM fractions (Fig. 1C) . The NADH activity clearly co-migrated with the IM (Fig. 1B ). This fractionation was not affected by the lack of AcrB, or TolC proteins. To confirm that there is no crosscontamination between the separated membranes, regions of the sedimentation gradient corresponding to the IM and OM were further purified by the density floatation fractionation. For this purpose, the appropriate fractions were pooled together as indicated in Fig. 1C and analyzed by floatation gradient centrifugation. Consistent with the previous studies, the IM fraction was resolved into a single peak with apparent buoyant density 1.18 g/ml. The OM fractionated into a single peak of density 1.23-1.26 g/ml (data not shown). Thus, the centrifugation in the sucrose density gradients efficiently separates the IM and OM. We estimate that after separation the non-specific cross-contamination between the two membranes is only about 5-10%.
AcrA is entirely located in the periplasm and postulated to interact with both the IM and OM. In three independent experiments, immunoblotting of the sucrose gradient fractions of membranes isolated from the wild type (ZK4) E. coli showed that 45±4% of AcrA was present in the IM and 26±1% of the protein co-migrated with the OM fractions (Fig. 1C, 2C ). The rest of AcrA is distributed in the intermediate-density fraction and on the top of the gradient. When the separated IM and OM were subjected to density floatation fractionation, AcrA co-floated with both membranes into 1.16-1.18 g/ml and 1.23-1.25 g/ml densities, respectively ( Fig. 1D ).
Previous studies showed that AcrA and AcrB form a stable complex in the IM (12) . If the OMbound AcrA remains associated with AcrB, the latter should also be present in the OM fractions. We found that the majority of AcrB (70±5%) co-fractionated with the IM on sucrose gradients (Fig. 1C) .
However, about 20% of AcrB co-migrated with the high-density OM and the intermediate-density
fractions. The immunoblotting analysis of sucrose fractions without heat denaturation of proteins prior to electrophoresis showed that high-density AcrB fractions contained several forms of protein: an AcrB monomer with an apparent molecular weight (MW) about 110 kDa and AcrB-containing high molecular weight (HMW) species with MWs more than 200 kDa (Fig. 1C ). To rule out protein aggregation as a possible cause of AcrB fractionation into high-density regions of sucrose, the separated OM fractions were subjected to floatation centrifugation. We found that similar to AcrA, AcrB remained bound to the OM during density floatation centrifugation (Fig. 1D) . Furthermore, when OM fractions were subjected to the second round of sucrose density centrifugation in the presence of salts and chaotropic agents both AcrA and AcrB still co-migrated with OM (data not shown). These results suggested that fractions of AcrA and AcrB could exist in a tight association with the OM.
TolC is essential for the co-fractionation of AcrAB with OM
To test if AcrB is required for AcrA association with the IM and OM, we fractionated AcrA in the AG102MB strain deficient of AcrB ( Fig. 2A, delAcrB) . We found that in the absence of AcrB the distribution of AcrA between the two membranes changed. Unlike AcrA in the WT strain, which fractionated 45%/26% with the IM and OM, respectively, in the delAcrB membranes 15±3% of total AcrA co-migrated with the OM and the majority of AcrA (48±1%) still co-migrated in the IM (Fig. 2C ).
In addition, the increased amounts of AcrA were present in the less than 1.16 g/ml region of sucrose gradient, which is mostly devoid of the IM proteins ( Fig. 2A ). This result suggested that AcrA is bound to the IM and OM even in the absence of AcrB. But the interaction of AcrA with the OM is severed and the protein is easily pulled away from the membranes.
Since more AcrA co-fractionates with the OM in the presence of AcrB, the AcrB transporter could be the driving component of association with the OM. AcrB contains a large periplasmic domain, which might establish interaction with TolC even in the absence of AcrA (14) . However, in the absence of AcrA we found only traces of AcrB in the OM fractions, even when AcrB and TolC were overproduced from the plasmids in the strain ECM2112 deficient of chromosomal copies of acrAB and tolC (Fig. 2B) . Thus, AcrB alone cannot co-fractionate with the OM. Only the presence of both proteins, AcrA and AcrB, in the cytoplasmic membrane leads to the formation of specialized regions that cofractionate in the sucrose gradient with the OM.
The outer membrane channel TolC has been reported to be indispensable for the multidrug resistance phenotype of E. coli (8) . However, the direct interaction between TolC and AcrAB has been elusive (12) . Consistent with previous reports, we found that the stable TolC trimers fractionate on sucrose gradients only with the OM (Fig. 1C ) (19) . Neither AcrA nor AcrB affected the localization of TolC (data not shown).
The distribution of AcrA between two membranes was not substantially affected by the lack of TolC ( Fig. 2A, delTolC) . In the delTolC mutant, the OM-bound AcrA constituted 21±3% of total AcrA, by guest on November 6, 2017
http://www.jbc.org/ Downloaded from whereas 48±4% of AcrA were present in the IM fractions (Fig. 2C) . However, in the delTolC membranes AcrA appears to be unstable and migrates in the SDS-PAGE as a shorter fragment with an apparent MW of 43 kDa. This result suggests that although TolC is not required for AcrA co-fractionation with the OM, the interaction with TolC stabilizes the AcrA structure. In contrast, we could not detect AcrB in the OM lacking TolC (Fig. 2B) . Thus, AcrB associates with the OM mainly through the binding to TolC. In the absence of TolC, the association with AcrA alone is not sufficient to keep AcrB in the OM. We conclude that the co-fractionation of AcrB with the OM is a result of the tight association between AcrAB complex and TolC.
AcrA, AcrB and TolC form a stable intermembrane complex in vivo
To determine whether co-fractionation on the sucrose gradient represents a physical interaction between the AcrAB complex and TolC, we carried out affinity co-purification experiments. For this purpose, the six-histidine (6His) tag was fused with the C-termini of each of the three components. (12) . For co-purification, the Triton X-100 extracts of total membrane proteins from the treated and untreated with DSP cells were subjected to affinity chromatography on Cu
2+
-charged NTA column. After purification, proteins and their complexes were analyzed by SDS-PAGE followed by silver staining (Fig. 3A) or immunoblotting with antibodies against AcrA, AcrB and TolC (Fig. 3B) . For the detection of cross-linked complexes, the reducing agent DTT and heat denaturation step were omitted during sample preparation for the SDS-PAGE (Fig. 3 and see Methods).
As shown on Fig. 3A , all tagged proteins efficiently bound to the column. Under the same conditions AcrA, AcrB or TolC without 6His-tag did not bind non-specifically to this column (Fig. 3A, bottom panel, lanes 5-7). In measurable quantities, all three components of the AcrAB-TolC complex copurify when the 6His-tag is fused to either AcrB or AcrA (Fig. 3) . Only trace amounts of complexes were co-purified when the 6His-tag was located on TolC (data not shown). Although no cross-linking is required for AcrA, AcrB and TolC co-purification, pre-treatment of cells with DSP increased the amounts of co-purified components.
The largest amounts of all three proteins were co-purified when the 6His-tag was located in AcrB His (Fig. 3A, top panel and 3B, lanes 1-4) . Even so, the amounts of AcrA or TolC in AcrB His preparations were insufficient to reproducibly detect these proteins by silver staining (Fig. 3A, lane 1) .
We used quantitative immunoanalysis to estimate the amounts of co-purified proteins. We found that 0.025±0.01 nmol of AcrA and 0.007±0.003 nmol of TolC are co-purified per 1 nmol of AcrB His . To confirm that AcrA and TolC form a specific complex with AcrB His we next analyzed cells pre-treated with DSP. In this case, the amounts of AcrA co-purified with AcrB His increased up to 20 fold. Silver staining of the corresponding gels showed that AcrA is the major protein that co-purifies with AcrB His (Fig. 3A, top panel, lanes 2-4). The amount of co-purified AcrA did not change when we analyzed cells lacking TolC suggesting that TolC is not required for AcrA-AcrB interaction (Fig. 3A, top panel, lanes 5-7) . In contrast to AcrA, DSP cross-linking resulted in very modest, 2-3 fold increase in co-purified TolC (Fig.   3B , bottom panel, lanes 3-4). Perhaps DSP is not an efficient cross-linker for TolC.
The immunoblotting analysis of AcrB His preparations without cleavage of cross-links by DTT prior to the SDS-PAGE showed that almost all AcrA and TolC were co-purified with AcrB His as highmolecular weight complexes (HMW) (Fig. 3B, lanes 3) . Some of these HMW complexes have also crossby guest on November 6, 2017
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Similar to AcrB
His , all three proteins were also co-purified when the 6His-tag was located in AcrA His (Fig. 3B, lanes 5-8) . The DSP cross-linking was not required for the co-purification of AcrB and TolC with AcrA His (Fig. 3B, lanes 5-6) . However, cross-linking visibly increased the amounts of the copurified complexes (Fig. 3B, lanes 7-8) .
The co-purification of TolC with AcrB His and AcrA His was detected only by immunoblotting (Fig.   3B , bottom panel 
AcrA cross-links to AcrB and TolC in vivo
Two cross-linked HMW complexes were co-purified with both AcrB His and AcrA His in sufficient amounts to allow further quantitative analysis. As judged by their mobility on SDS-PAGE, these two complexes were similar to the previously described in vivo complexes designated C1 and C2 (12) . Both C1 and C2 complexes were immunodetected by anti-AcrA and anti-AcrB antibodies indicating that AcrA and AcrB are present in these complexes (Fig. 3B ).
To determine if other proteins are also present in C1 or C2, protein bands were excised from the gels and after reversion of cross-links by overnight incubation with 100 mM DTT were analyzed by the second SDS-PAGE. Using silver staining we detected only two proteins corresponding by MWs to AcrA and AcrB (Fig. 3C ). These two proteins reacted with anti-AcrA and anti-AcrB antibodies, respectively.
Thus, the predominant components of C1 and C2 complexes are AcrA and AcrB. Consistent with the previous in vivo cross-linking studies (12) AcrA-AcrB complexes were purified from the cells lacking TolC suggesting that TolC does not contribute to the formation of these complexes (Fig. 3A, lanes 5-7) .
Since both AcrA and AcrB were shown to form oligomers, the MW difference between C1 and C2 could be due to the differences in the subunit composition of these two complexes.
Previous in vivo cross-linking followed by immunoblotting of total membranes with anti-AcrA and anti-AcrB antibodies did not detect AcrA-or AcrB-containing HMW complexes, which could also contain TolC (12) . In this study, we found that even after the treatment with DSP the amounts of purified tri-partite AcrAB-TolC complexes were very small (Fig. 3B, bottom panel) . Such amounts of complexes would be very difficult to detect by the immunoblotting of total membrane fractions. In contrast, the enrichment through co-purification allowed us to identify distinct TolC-containing HMW species present in AcrA His and AcrB His preparations. We found that TolC co-purified with AcrB His migrates in SDS-PAGE as a cascade of bands with apparent MW ~ 220 kDa (Fig. 3B , bands designated CC1). This MW is higher than that of the purified trimeric TolC (~ 105 kDa) suggesting that TolC is bound to one or both components of the complex. However, whether the 220 kDa complex also contains AcrA or AcrB remained unclear because the MW of this complex overlaps with the AcrA-AcrB complex C2.
The formation of the CC1 complex was independent of DSP treatment. In contrast, TolCcontaining HMW complexes identified in the AcrA His preparations (Fig. 3B , bands designated CC2, lanes 7-8) were purified only from the DSP-treated cells. The MW of the CC2 complex was estimated to be ~180 kDa. The cross-reactivity with both anti-TolC and anti-AcrA antibodies suggested that CC1 is a cross-linked complex between AcrA and TolC. Thus, in vivo AcrA cross-links to both AcrB and TolC.
In addition to AcrB and TolC, two other proteins seem to co-purify with AcrA His (Fig. 3A, bottom panel, lanes 1-2). Using mass spectrometry we identified the 33 kDa protein as cytochrome o ubiquinol oxidase subunit II (CyoA). Like AcrA, CyoA is a periplasmic lipoprotein associated with the IM (23).
The possible functional interaction between CyoA and AcrA is under investigation. At least four other unknown proteins were cross-linked and co-purified with TolC His (Fig. 3A, bottom panel, lanes 3-4) .
These proteins await further analysis.
Downloaded from
Assembly of AcrAB-TolC complex does not require transport activity
To investigate whether an active transport event is required for the assembly of AcrAB-TolC we introduced D408A substitution into AcrB His , AcrB408 His , and evaluated this mutant in the functional and complex formation assays. This mutation neutralizes a highly conserved negative charge of Asp408 within the transmembrane segment 4 of AcrB and presumably inactivates the transporter (14) .
Consistent with previous studies AcrB408
His failed to complement the multidrug resistance phenotype. The AG100AX E. coli cells expressing the plasmid-encoded AcrA-AcrB408 His remained highly susceptible to a broad range of tested compounds (Table 2 ). In some instances the presence of a defective variant of certain proteins prevented a function of multi-component complexes (24,25).
Consistent with previous data, we found that the overexpression of the functional AcrAB His in the WT
E. coli caused a 2-4 fold increase in MICs of tested antimicrobials (26). In contrast, when the
AcrB408
His mutant was present in the WT E. coli the MICs of many antimicrobials dropped almost to the level of the highly susceptible AG100AX strain ( His migrated in the sucrose gradient as a single broad peak (data not shown).
The co-purification data provided a possible explanation for the failed separation of two membranes in the presence of AcrB408 His (Fig. 4A) We next used ionophores CCCP, nigericin and valinomycin to investigate the effect of proton-motive force depletion on the assembly and stability of the AcrAB-TolC complex ( Fig. 4B and 4C). For this purpose, cells grown in the LB medium under aerobic conditions to exponential growth phase were treated with increasing concentrations of CCCP prior to cell disruption. The range of CCCP concentrations was in excess of previously reported concentrations required to fully dissipate the proton-motive force (27,28). Cells untreated and treated with CCCP were then processed for the affinity co-purification experiments. We found that pre-treatment with CCCP did not disrupt interactions within the complex. In contrast, the amounts of both AcrA and TolC co-purified with AcrB His slightly increased. Quantification of immunoblots with antibodies that recognize the components of the complex showed that, at 20 µM CCCP, up to 3 fold more AcrA and twice as much TolC were co-purified with AcrB His (Fig. 4C) . The CCCP pre-treatment of cells expressing AcrA-
His did not affect the amounts of co-purified AcrA (Fig. 4B and 4C) . However, the amounts of TolC slightly increased. Similarly, pre-treatment of cells with nigericin, valinomycin or combination of both ionophores in the presence of potassium ions led to small increases of AcrABTolC complex stability (data not shown).
Taken together these results suggest that proton-motive force, which drives translocation of substrates by AcrAB-TolC complex, is not required for the complex assembly. The AcrB408
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Antibiotics affect AcrAB-TolC complex assembly
The experiments described above demonstrated that the AcrAB-TolC complex is assembled even in the absence of known AcrB substrates and proton-motive force. To investigate whether the presence of substrates affects the process of complex assembly or its stability we treated E. coli cells prior to co-purification experiments with OLE, PUR and PRO in concentrations below MIC values ( Table 2 , substantially as can be clearly seen on silver stained SDS-polyacrylamide gel (Fig. 5A) . Depending on the drug 3-8 fold more AcrA were co-purified with AcrB (Fig. 5B) . The inhibitor MC-207,110, which was previously demonstrated to be a competitive inhibitor, showed the strongest effect with up to a ten fold increase in the amounts of AcrA co-purified with AcrB His . We also detected the elevated amounts of TolC (about a two fold increase), which were co-purified in the presence of drugs and the inhibitor. We conclude that the presence of substrates leads to the increased amounts of purified tripartite complexes. Association between AcrA and AcrB is affected most profoundly. The AcrABTolC complex exists in E. coli cells even in the absence of drugs (Fig. 3) . Thus, drugs and the inhibitor most probably stabilize interactions within the complex.
DISCUSSION
A main question in the field of transport in Gram-negative bacteria bounded by two membranes is how translocation of substrates across these membranes is coordinated. We show here that the multidrug efflux complex AcrAB tightly binds to the TolC channel potentially creating a direct link between the cytoplasmic and the outer membranes. Two different approaches, sucrose gradient fractionation and copurification studies are consistent with each other and provide a strong evidence for the existence of the stable intermembrane AcrAB-TolC complex. Fractions of AcrA and AcrB proteins were separated into two peaks corresponding to the IM and the OM (Fig. 1) . AcrA co-localization with the OM was not surprising since a number of other periplasmic proteins involved in coordination of processes spatially separated in two different membranes were found to co-fractionate with both membranes (30,31).
However, the fact that AcrA was found in both membranes does not necessarily mean that the same AcrA molecule is in simultaneous contact with both membranes. Fractionation of AcrB with the OM and the requirement of its presence for the tight AcrA interaction with the OM points onto such possibility ( Fig. 1 and 2). In contrast to AcrA, which is anchored in the IM through the N-terminal lipid moiety, AcrB is a polytopic membrane protein and is unlikely to be released from the IM. Thus, OM-bound AcrB cofractionates with the high density regions of the IM. TolC is required for AcrB fractionation with the OM suggesting that these high-density regions are the sites of tight adhesion between AcrAB and TolC.
Interestingly, AcrA was present in the OM fractions even in the absence of TolC (Fig. 2A) . It is possible that the interaction with AcrB changes the conformation of AcrA so that it can reach the OM.
Since TolC is not required for AcrA binding to the OM possibly another OM protein or lipids serve as an anchor for AcrA in the OM. Several unidentified proteins were cross-linked only to AcrA His or TolC His (Fig. 3A) . At least one of these proteins appears to be present in both preparations. Future analysis of this protein might point onto this missing link in the AcrAB-TolC assembly.
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Anchoring of AcrA into the OM might represent an intermediate step in the complex assembly. In the absence of AcrA, we did not detect AcrB in the OM even when both AcrB and TolC were overproduced in the cells. Thus, the role of AcrA in the complex assembly could be to reach the OM and bring AcrB and TolC into close proximity. The observation that AcrA can be cross-linked to both AcrB and TolC in vivo provides an additional support to the notion that assembly of the complex is possibly mediated by AcrA (Fig. 3) .
We estimate there are up to ~5000-7000 copies of AcrA per cell during the exponential phase AcrA-AcrB complex with a modest increase in the amounts of co-purified TolC (Fig. 5) . Thus, substrates affect AcrAB-TolC complex stability. Since AcrA interaction with AcrB is affected more profoundly, we conclude that substrate binding could trigger conformational changes in both AcrA and AcrB. Two AcrA homologs, HlyD and EmrA, involved in the transport of α−hemolysin and drugs, respectively, were
shown to interact directly with their substrates (34, 35) . Thus, substrates might first interact with and induce conformational changes in AcrA. This new conformation of AcrA could promote stable association with AcrB ( Fig. 5A ) and conformational changes in AcrB. Whether these conformational changes are concurrent with or required for the recruitment of TolC remains unclear.
Energy is not required to assemble AcrAB-TolC complex. Dissipation of the proton-motive force by ionophores or mutation of essential D408 in AcrB only increased the stability of the complex (Fig. 4) .
Similarly, inhibition of the ATPase activity of HlyB, the IM transporter of α−hemolysin exporter HlyBDTolC, did not affect complex assembly (4). The assembled AcrAB-TolC complex is sufficiently stable for co-purification of all three compounds by Cu 2+ -NTA chromatography (Fig. 3) . Perhaps, energy is required to disassemble the complex and recycle its components. AcrA were quantified as in Fig. 1D . The amounts of AcrA associated with the IM or OM were calculated from the appropriate fractions as a percent of the total AcrA present in all fractions.
Averages and standard deviations (SD) of three independent experiments are shown. by guest on November 6, 2017
